|
KMID : 0620920230550050898
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 5 p.898 ~ p.909
|
|
|
Glia maturation factor beta deficiency protects against diabetic osteoporosis by suppressing osteoclast hyperactivity
|
|
Si Shi
Gu Hui-Jie
Jinyuan Xu
Wan Sun
Caiyin Liu
Tong Zhu
Juan Wang
Furong Gao
Jieping Zhang
Qingjian Ou
Caixia Jin
Jingying Xu
Hao Chen
Jiao Li
Guotong Xu
Haibin Tian
Lixia Lu
|
|
|
Abstract
|
|
|
|
Excessive osteoclast activation, which depends on dramatic changes in actin dynamics, causes osteoporosis (OP). The molecular mechanism of osteoclast activation in OP related to type 1 diabetes (T1D) remains unclear. Glia maturation factor beta (GMFB) is considered a growth and differentiation factor for both glia and neurons. Here, we demonstrated that Gmfb deficiency effectively ameliorated the phenotype of T1D-OP in rats by inhibiting osteoclast hyperactivity. In vitro assays showed that GMFB participated in osteoclast activation rather than proliferation. Gmfb deficiency did not affect osteoclast sealing zone (SZ) formation but effectively decreased the SZ area by decreasing actin depolymerization. When GMFB was overexpressed in Gmfb-deficient osteoclasts, the size of the SZ area was enlarged in a dose-dependent manner. Moreover, decreased actin depolymerization led to a decrease in nuclear G-actin, which activated MKL1/SRF-dependent gene transcription. We found that pro-osteoclastogenic factors (Mmp9 and Mmp14) were downregulated, while anti-osteoclastogenic factors (Cftr and Fhl2) were upregulated in Gmfb KO osteoclasts. A GMFB inhibitor, DS-30, targeting the binding site of GMFB and Arp2/3, was obtained. Biocore analysis revealed a high affinity between DS-30 and GMFB in a dose-dependent manner. As expected, DS-30 strongly suppressed osteoclast hyperactivity in vivo and in vitro. In conclusion, our work identified a new therapeutic strategy for T1D-OP treatment. The discovery of GMFB inhibitors will contribute to translational research on T1D-OP.
|
|
|
KEYWORD
|
|
|
Diabetes complications, Type 1 diabetes
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|